Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression
- PMID: 14627997
- DOI: 10.1038/sj.npp.1300341
Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression
Abstract
This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After 1 week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.
Similar articles
-
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70. doi: 10.1016/j.euroneuro.2004.01.002. Eur Neuropsychopharmacol. 2004. PMID: 15589385 Clinical Trial.
-
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.J Clin Psychiatry. 2006 Feb;67(2):288-96. doi: 10.4088/jcp.v67n0217. J Clin Psychiatry. 2006. PMID: 16566626 Clinical Trial.
-
Paroxetine versus placebo: a double-blind comparison in depressed patients.J Clin Psychiatry. 1992 Dec;53(12):434-8. J Clin Psychiatry. 1992. PMID: 1487471 Clinical Trial.
-
A review of pharmacotherapy of major depression in children and adolescents.Psychiatr Serv. 2000 May;51(5):627-33. doi: 10.1176/appi.ps.51.5.627. Psychiatr Serv. 2000. PMID: 10783181 Review.
-
Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements.J Affect Disord. 2010 Jan;120(1-3):16-23. doi: 10.1016/j.jad.2009.08.011. J Affect Disord. 2010. PMID: 19735945 Review.
Cited by
-
Involvement of PI3K/Akt Signaling Pathway and Its Downstream Intracellular Targets in the Antidepressant-Like Effect of Creatine.Mol Neurobiol. 2016 Jul;53(5):2954-2968. doi: 10.1007/s12035-015-9192-4. Epub 2015 May 6. Mol Neurobiol. 2016. PMID: 25943184
-
Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.Trials. 2010 Feb 26;11:21. doi: 10.1186/1745-6215-11-21. Trials. 2010. PMID: 20187947 Free PMC article. Clinical Trial.
-
Effects of Kaixin Jieyu Decoction () on behavior, monoamine neurotransmitter levels, and serotonin receptor subtype expression in the brain of a rat depression model.Chin J Integr Med. 2014 Apr;20(4):280-5. doi: 10.1007/s11655-014-1343-0. Epub 2014 Feb 24. Chin J Integr Med. 2014. PMID: 24567255
-
Paroxetine versus other anti-depressive agents for depression.Cochrane Database Syst Rev. 2014 Apr 3;2014(4):CD006531. doi: 10.1002/14651858.CD006531.pub2. Cochrane Database Syst Rev. 2014. PMID: 24696195 Free PMC article.
-
Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.Neuropsychiatr Dis Treat. 2021 Dec 18;17:3735-3741. doi: 10.2147/NDT.S340309. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34955641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical